DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Netazepide is an investigational drug.
There have been 6 clinical trials for Netazepide. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2011.
The most common disease conditions in clinical trials are Carcinoid Tumor, Atrophy, and Barrett Esophagus. The leading clinical trial sponsors are Trio Medicines Ltd., University of Cambridge, and National Institute for Health Research, United Kingdom.
There are five US patents protecting this investigational drug and seventy-three international patents.
Recent Clinical Trials for Netazepide
|YF476 in Barrett's Esophagus||Columbia University||Phase 2|
|YF476 in Barrett's Esophagus||University of Cambridge||Phase 2|
|YF476 in Barrett's Esophagus||Trio Medicines Ltd.||Phase 2|
Top disease conditions for Netazepide
Top clinical trial sponsors for Netazepide
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Netazepide||Start Trial||Benzodiazepine derivatives as CCK2/gastrin receptor antagonists||TRIO MEDICINES LTD (Brighton East Sussex, GB)||Start Trial|
|Netazepide||Start Trial||Benzodiazepine derivatives useful as CCK-receptor antagonists||Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)||Start Trial|
|Netazepide||Start Trial||Process of preparing benzodiazepine compounds useful as antagonists of CCK or of gastrine||Ferring-Research Limited (Middlesex, GB) Yamanouchi Pharmaceutical Co. Ltd. (Tokyo, JP)||Start Trial|
|Netazepide||Start Trial||Benzodiazepin derivatives useful as CCK-receptor antagonists||Ferring BV (NL) Yamanouchi Pharmaceutical Co. Ltd. (Tokyo, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|